UnknownNot Applicable

Clinical Analysis of Simultaneous Pancreas-kidney Transplantation for End-stage Renal Disease Associated With Diabetes Mellitus

China200 participantsStarted 2022-09-01

Plain-language summary

The first pancreas transplantation was performed in 1966, by 2015, more than 40,000 pancreas transplantation have been performed worldwide. Nevertheless, only several Chinese organ transplant centers carry out SPK because of surgery complications. simultaneous pancreas-kidney transplantation is a new and promising therapeutic option for the treatment for type 1 diabetes mellitus patients and end-stage renal disease. the preliminary treatment results are summarized to promote the further development of this work in China.

Who can participate

Age range16 Years – 65 Years

SexALL

See this in plain English?

AI-rewrites the medical criteria so a patient or caregiver can understand them. Always confirm with the trial site.

Inclusion criteria

✓. Clinical diagnosis of Diabetes patients with end-stage renal disease;
✓. First time receiving SPKT;

Exclusion criteria

✕. Pulmonary infection, urinary tract infection, hematuria CMV or BK virus infection occurred during treatment;
✕. Using a large number of abnormal biological products (blood transfusion, plasma or coagulation factors) may contain foreign DNA;
✕. Loss of graft due to thrombosis or AR;
✕. Patients who are pregnant or have malignant tumors or patients with a history of cell therapy, whose tumor signals interfere with dd-cfDNA detection;
✕. Patients who have poor compliance during treatment or suffer from mental illness.

What they're measuring

Patient survival & pancreas graft survival & renal graft survival

Timeframe: 12 months

Trial details

NCT IDNCT05497232

SponsorSecond Affiliated Hospital of Guangzhou Medical University

Sponsor typeOTHER

Study typeINTERVENTIONAL

Primary completion2023-01-01

View on ClinicalTrials.gov More Diabetes Mellitus；Uremia trials